Overview

• US biopharma developer's Q1 net loss widened yr/yr on higher R&D expenses

• Company expects cash position to fund operations into mid-2027

• FDA granted Fast Track designation to lead candidate for ovarian cancer

Outlook

• Company expects Phase 1a interim data for CTIM-76 trial in June 2026

• Phase 1a interim data for CT-95 trial expected in September 2026

• Company expects cash and cash equivalents to fund operations into mid-2027

Result Drivers

• HIGHER R&D EXPENSES - Increased spending on CTIM-76, CT-202, CT-95 programs and higher personnel-related costs drove up R&D expenses

• HIGHER ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher salaries, share-based compensation, and professional fees

• LOWER INTEREST INCOME - Other income declined due to lower interest income on cash and cash equivalents

Company press release: ID:nGNX5nTPQM

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Context Therapeutics Inc is $5.50, about 125.4% above its May 5 closing price of $2.44

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.